The Clinical Trial Regulation is currently being discussed. As patients, researchers, doctors, scientists and civil society representatives we would like to draw your attention not only to the dangers it encompasses but also to the opportunities it brings along.
The International Society of Drug Bulletins issued a statement today to the members of European Parlament to request:
The protection of human subjects must be upheld & citizens’ right to information must be strengthened
On 18 June 2012, the EU Commission published a draft concept paper for public consultation on the “Introduction of fees to be charged by the European Medicines Agency for pharmacovigilance”.
The draft paper on the quality review of documentssubmitted for consultation by the EMA does not reflect the spirit of the new pharmacovigilance legislation, which is to prevent druginduced harm.
The draft paper on the quality review of documentssubmitted for consultation by the EMA does not reflect the spirit of the new...
Broadening access to signal is a positive step, but access to VigiBase is also needed
Some improvements, but risks of DTCA (direct-to-consumer advertising) remain
read english (
ISDB - International Society of Drug bullettins
Contact details:
President: president@isdbweb.org
Webmaster: maria.font@ulss20.verona.it
© 2013